Navigating the Challenges of 340B Pharmacies

The 340B Drug Pricing Program creates real opportunity for covered entities - discounted medications, extended reach into underserved communities, and revenue that funds broader services. But that opportunity comes with a compliance burden that too many organizations are not fully prepared for. Regulatory scrutiny is increasing, operational requirements are intensifying, and the organizations that are not building serious internal systems are falling behind.

What the 340B program was built to do

Established in 1992 under the Public Health Service Act, the 340B program enables eligible healthcare organizations to purchase prescription medications from manufacturers at discounted rates. Covered entities - federally qualified health centers, disproportionate share hospitals, and other safety-net providers - use those savings to stretch limited resources and improve medication access for patients who cannot easily afford care otherwise.

The program works when covered entities run it with rigor. It creates serious problems when they treat compliance as an afterthought.

The three categories of challenge

Regulatory compliance

HRSA audits. Covered entities must maintain compliance across eligibility verification, patient identification, and diversion prevention. HRSA audits verify all of it, and the process is resource-intensive even for well-prepared organizations. Teams that have not built systems for documentation, audit trails, and evidence management find themselves scrambling when an audit arrives.

A shifting regulatory environment. The rules governing 340B eligibility, patient verification requirements, and diversion prevention have changed repeatedly over the program's history - and continue to evolve. Policy shifts create operational and reimbursement risk for organizations that are not tracking them actively. Covered entities need to stay ahead of regulatory changes, not react to them.

Operational requirements

Inventory management. Tracking 340B-eligible prescriptions separately from non-340B prescriptions is not a small task. Fluctuating patient demand, multiple dispensing locations, and varying payer rules all complicate oversight. Without precise tracking, organizations risk both compliance failures and financial waste.

EHR integration. Incorporating 340B requirements into existing electronic health record systems is one of the more persistent operational challenges covered entities face. Many pharmacy management platforms were not built with 340B compliance in mind, which means additional software layers or custom integration work. The organizations that handle this well use solutions that work alongside their existing EHR rather than requiring a full replacement.

Financial stability

Reimbursement variability. Reimbursement rates from payers and pharmacy benefit managers vary significantly, and some PBMs have actively contested covered entities' ability to use contract pharmacies at all. Managing that variability - and ensuring that 340B-purchased drugs generate appropriate reimbursement - requires strong claims processing and ongoing payer relations.

Contract pharmacy network management. For covered entities using contract pharmacy arrangements, building a solid network is only the first step. Managing those relationships while maintaining compliance around inventory, data reporting, and audit readiness is an ongoing operational responsibility. A contract pharmacy arrangement that is not actively managed becomes a compliance liability.

What strong 340B management looks like

The organizations that run 340B programs successfully tend to share a few characteristics. They have dedicated compliance infrastructure - not just a part-time staff member who also handles other duties. They have invested in data management that connects patient eligibility, dispensing records, and audit documentation in one place rather than across disconnected spreadsheets and systems. And they treat compliance as a continuous operating discipline rather than something to address when HRSA sends a letter.

Jacob Sacks, Founder & CEO of Remy: "In today's regulatory environment, 340B consultants can't afford to be results-driven. You need to be results determined."

That distinction matters. Results-driven means optimizing for the outcome you want. Results-determined means building the systems that make that outcome repeatable - even when regulations shift, payers push back, or audits arrive.

How infusion and telemedicine extend what 340B makes possible

For covered entities that have built solid 340B operations, the natural next step is putting those discounted drug acquisitions to work through clinical service expansion. Infusion sites - whether in-house or through partnership - allow covered entities to administer biologics for conditions like rheumatoid arthritis, Crohn's disease, and multiple sclerosis using 340B-purchased medications. That combination of discounted acquisition and infusion reimbursement creates a meaningful revenue and care access opportunity.

Telemedicine expands geographic reach without the overhead of additional physical locations, extending patient engagement beyond the clinic walls and improving continuity of care.

Neither of those opportunities is accessible to organizations that are struggling with the compliance fundamentals. Getting the 340B foundation right is what makes the expansion possible.

Starting with a clear-eyed assessment

Every organization's 340B program has different strengths and different vulnerabilities. The right starting point is an honest look at where the gaps are - in compliance documentation, in EHR integration, in contract pharmacy management, in reimbursement capture - before trying to optimize what is already working.

If your organization is facing pressure from HRSA, navigating a contract pharmacy dispute, or simply trying to build a more durable compliance infrastructure, contact Remy for a free assessment of where your program stands and what a stronger system looks like.